Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma: A Retrospective Cohort Study

5-Fluorouracile, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) has not been extensively used in the neoadjuvant setting because of concerns with safety and toxicity. We evaluated our institutional experience with neoadjuvant FOLFIRINOX in borderline resectable pancreatic adenocarcinoma (BRPAC...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Medicine (Baltimore)
Autores principales: Paniccia, Alessandro, Edil, Barish H., Schulick, Richard D., Byers, Joshua T., Meguid, Cheryl, Gajdos, Csaba, McCarter, Martin D.
Formato: Artigo
Lenguaje:Inglês
Publicado: Wolters Kluwer Health 2014
Materias:
7100
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4602784/
https://ncbi.nlm.nih.gov/pubmed/25501072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000000198
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares